Physician profile
Elizabeth Cabrera
NPI 1245242262
$1,622.07
in general payments reported to CMS, 2019-2025
19 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.33 · 2022: $147 · 2023: $186 · 2024: $738 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.78 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $297.74 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $292.46 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $164.66 | 2024-2025 | |
| Amgen INC. | $134.50 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $84.53 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $74.86 | 2022-2025 | Dupixent |
| Biofrontera INC. | $61.70 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $60.69 | 2022-2024 | |
| Journey Medical Corporation | $59.26 | 2022-2023 | |
| Ucb, INC. | $58.22 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $48.19 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $47.13 | 2022-2025 | Nemluvio |
| Organon LLC | $43.04 | 2024-2025 | |
| Mimedx Group, INC. | $42.52 | 2024 | |
| Abbvie INC. | $39.37 | 2022-2023 | Rinvoq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.86 | 2024 | Cabtreo |
| Janssen Biotech, INC. | $27.33 | 2023 | Tremfya |
| Abbott Laboratories | $24.03 | 2025 | Cardiomems |
| Convatec INC. | $23.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.